IN2014MN01488A - - Google Patents

Info

Publication number
IN2014MN01488A
IN2014MN01488A IN1488MUN2014A IN2014MN01488A IN 2014MN01488 A IN2014MN01488 A IN 2014MN01488A IN 1488MUN2014 A IN1488MUN2014 A IN 1488MUN2014A IN 2014MN01488 A IN2014MN01488 A IN 2014MN01488A
Authority
IN
India
Prior art keywords
mixture
subunits
subunit
mol
relative
Prior art date
Application number
Inventor
Laura Akullian
Gui Liu
Timothy B Lowinger
Dennis Mcgillicuddy
Cheri Stevenson
John Van Duzer
Mao Yin
Aleksandr Yurkovetskiy
Original Assignee
Mersana Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mersana Therapeutics Inc filed Critical Mersana Therapeutics Inc
Publication of IN2014MN01488A publication Critical patent/IN2014MN01488A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)

Abstract

The invention described herein provides a mixture comprising polymer molecules or salts thereof wherein a polymer molecule in the mixture comprises covalently bound subunits L K and M wherein the average molecular weight of the polymer molecules in the mixture is about 50 kDa to about 200 kDa wherein the mole percentage of subunit M relative to the total amount of subunits in the mixture is about 90.5 to about 96 mol% v1 herein the mole percentage of subunit K relative to the total amount of subunits in the mixture is about 2.8 to about 7.3 mol% and wherein the mole percentage of subunit L is about relative to the total amount of subunits in the mixture 1. 2 to about 2. 2 mol%.
IN1488MUN2014 2011-12-23 2012-12-21 IN2014MN01488A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161580016P 2011-12-23 2011-12-23
US201261639654P 2012-04-27 2012-04-27
PCT/US2012/071477 WO2013096901A1 (en) 2011-12-23 2012-12-21 Pharmaceutical formulations for fumagillin derivative-phf conjugates

Publications (1)

Publication Number Publication Date
IN2014MN01488A true IN2014MN01488A (en) 2015-04-17

Family

ID=48669583

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1488MUN2014 IN2014MN01488A (en) 2011-12-23 2012-12-21

Country Status (9)

Country Link
US (1) US20130189218A1 (en)
EP (1) EP2794582A1 (en)
JP (1) JP2015503635A (en)
KR (1) KR20140121827A (en)
CN (1) CN104024236A (en)
IN (1) IN2014MN01488A (en)
TW (1) TW201332574A (en)
UY (1) UY34542A (en)
WO (1) WO2013096901A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2697674T3 (en) 2011-11-01 2019-01-25 Bionomics Inc Procedures to block the growth of cancer stem cells
CA2966005C (en) 2014-10-31 2021-04-27 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
EP3229844B1 (en) 2014-12-09 2020-03-04 AbbVie Inc. Antibody drug conjugates with cell permeable bcl-xl inhibitors
RU2017123942A (en) 2014-12-09 2019-01-11 Эббви Инк. BCL-XL INHIBITING COMPOUNDS WITH LOW CELL PERMEABILITY AND ANTIBODY MEDICINES CONJUGATES INCLUDING THEM
EP3383909B1 (en) 2015-11-30 2020-06-17 AbbVie Inc. Anti-human lrrc15 antibody drug conjugates and methods for their use
JP2019501124A (en) 2015-11-30 2019-01-17 アッヴィ・インコーポレイテッド Anti-huLRRC15 antibody drug conjugate and method of use thereof
US10745487B2 (en) 2016-03-22 2020-08-18 Bionomics Limited Method of treating cancer by administering an anti-LGR5 monoclonal antibody
RS61659B1 (en) 2016-05-17 2021-04-29 Abbvie Biotherapeutics Inc Anti-cmet antibody drug conjugates and methods for their use
EP3464400B1 (en) * 2016-06-03 2022-04-06 Novacyte Therapeutics Company.,LTD Polymer linkers and their uses
MX2018015268A (en) 2016-06-08 2019-08-12 Abbvie Inc Anti-cd98 antibodies and antibody drug conjugates.
RS61828B1 (en) 2016-06-08 2021-06-30 Abbvie Inc Anti-b7-h3 antibodies and antibody drug conjugates
JP2019526529A (en) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド Anti-B7-H3 antibody and antibody drug conjugate
MX2018015284A (en) 2016-06-08 2019-09-18 Abbvie Inc Anti-egfr antibody drug conjugates.
MX2018015272A (en) 2016-06-08 2019-08-12 Abbvie Inc Anti-cd98 antibodies and antibody drug conjugates.
WO2017214456A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
CN116059201A (en) 2016-06-08 2023-05-05 艾伯维公司 Anti-EGFR Antibody Drug Conjugate
CN109641962A (en) 2016-06-08 2019-04-16 艾伯维公司 Anti-B7-H3 Antibodies and Antibody Drug Conjugates
CN109562190A (en) 2016-06-08 2019-04-02 艾伯维公司 Anti-EGFR Antibody Drug Conjugates
PE20210320A1 (en) 2018-06-01 2021-02-16 Novartis Ag BINDING MOLECULES AGAINST BCMA AND THE USES OF THEM
BR112021000021A2 (en) * 2018-07-03 2021-03-30 Fennec Pharmaceuticals, Inc. ANhydrous SODIUM THYOSULFATE AND FORMULATIONS OF THE SAME
KR20210099614A (en) 2018-12-04 2021-08-12 노파르티스 아게 Binding molecules for CD3 and uses thereof
PE20212185A1 (en) 2019-02-18 2021-11-11 Lilly Co Eli FORMULATION OF THERAPEUTIC ANTIBODIES
UY38701A (en) 2019-05-21 2020-12-31 Novartis Ag MOLECULES OF BINDING TO CD19, CONJUGATES, COMPOSITIONS THAT INCLUDE THEM AND USES OF THE SAME
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
CN114585651A (en) 2019-08-08 2022-06-03 再生元制药公司 Novel antigen binding molecular forms
AU2020379735A1 (en) 2019-11-05 2022-05-26 Regeneron Pharmaceuticals, Inc. N-terminal SCFV multispecific binding molecules
CN115052663B (en) 2020-01-08 2026-06-09 辛瑟斯治疗股份有限公司 ALK5 inhibitor conjugates and uses thereof
JP7859981B2 (en) 2020-03-06 2026-05-15 ジーオー セラピューティクス,インコーポレイテッド Antiglyco-CD44 antibody and its use
WO2021195513A1 (en) 2020-03-27 2021-09-30 Novartis Ag Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
AR124681A1 (en) 2021-01-20 2023-04-26 Abbvie Inc ANTI-EGFR ANTIBODY-DRUG CONJUGATES
EP4301782A1 (en) 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
JP2024531915A (en) 2021-08-05 2024-09-03 ジーオー セラピューティクス,インコーポレイテッド Anti-glyco-MUC antibodies and uses thereof
WO2023034569A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
JP2024534910A (en) 2021-09-03 2024-09-26 ジーオー セラピューティクス,インコーポレイテッド Anti-glycolic LAMP1 antibodies and uses thereof
WO2023066251A1 (en) * 2021-10-19 2023-04-27 同宜医药(苏州)有限公司 Conjugate drug preparation, preparation method therefor and use thereof
CN121002062A (en) 2023-01-13 2025-11-21 再生元制药公司 FGFR3 binding molecules and their usage
WO2024258967A1 (en) 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290807A (en) * 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
BRPI0820229A2 (en) * 2007-11-28 2017-05-09 A Stevenson Cheri biocompatible biodegradable fumagillin analog conjugates
JP2012528240A (en) * 2009-05-28 2012-11-12 メルサナ セラピューティックス, インコーポレイテッド Polyal-drug conjugates containing variable rate release linkers

Also Published As

Publication number Publication date
WO2013096901A1 (en) 2013-06-27
EP2794582A1 (en) 2014-10-29
US20130189218A1 (en) 2013-07-25
TW201332574A (en) 2013-08-16
UY34542A (en) 2013-07-31
JP2015503635A (en) 2015-02-02
WO2013096901A8 (en) 2014-08-07
CN104024236A (en) 2014-09-03
KR20140121827A (en) 2014-10-16

Similar Documents

Publication Publication Date Title
WO2013096901A8 (en) Pharmaceutical formulations for fumagillin derivative-phf conjugates
EA201390600A1 (en) THERAPEUTIC NANOPARTICLES WITH COPOLYMERS WITH A GREAT MOLECULAR WEIGHT
UA111820C2 (en) MODIFIED BINDING PROTEIN INHIBITING VEGF-A-RECEPTOR INTERACTION
CY1120557T1 (en) ANTI-PSEUDOMONAS PSL BINDING MOTORS AND THEIR USES
GB201008902D0 (en) Membrane enhanced polymer sythesis
MX347644B (en) Star macromolecules for personal and home care.
EP2812438A4 (en) MANIPULATED ESCHERICHIA COLI STRAIN FOR PRODUCING POLY-R-3-HYDROXYALCANOATE POLYMERS HAVING A DEFINED MONOMERIC MOLECULAR COMPOSITION AND ASSOCIATED METHODS
MX2010009154A (en) Conjugated factor viii molecules.
JP2012255007A5 (en)
EP2621480A4 (en) LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR THE ADMINISTRATION OF OLIGONUCLEOTIDES
EP2635265A4 (en) LOW MOLECULAR WEIGHT CYCLIC AMINE CONTAINING CATIONIC LIPIDS FOR THE ADMINISTRATION OF OLIGONUCLEOTIDES
MX2013007537A (en) Pharmaceutical formulation comprising a biopharmaceutical drug.
WO2012007324A3 (en) Stabilized factor viii variants
EA201200617A1 (en) POLYMERS ON THE BASIS OF CYCLODEXTRINE FOR DELIVERY OF MEDICINES
MX2012000575A (en) ε-POLYLYSINE CONJUGATES AND USE THEREOF.
EP2555741A4 (en) Sprayable composition comprising high molecular weight charged polymer
UA101497C2 (en) Conjugates of factor ix with increased half-life
EP2785779A4 (en) ASPHALT COMPOSITIONS HAVING IMPROVED PROPERTIES AND COATINGS AND ASSOCIATED METHODS
EP2557120A4 (en) COMPOSITION FORMING THERMO-CURED FILM HAVING PHOTO-ALIGNMENT PROPERTIES
WO2013186632A3 (en) Conjugates of biologically active molecules to functionalized polymers
IN2014CN03735A (en)
EA201270186A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING MODIFIED FUKANS FOR USE WHEN TREATING FIBROUS ADHESIVES AND OTHER VIOLATIONS
EP2718337A4 (en) PRODUCTION OF HIGHLY REACTIVE LOW MOLECULAR WEIGHT PIB OLIGOMERS
DE602006020256D1 (en) LOW VOLUMES OF HIGH-MOLECULAR POLYMERS FOR VISCOSITY INCREASE IN AQUEOUS / AQUEOUS-2-PHASE LIQUIDS
BRPI0923381A2 (en) friction reducing polymers for low molecular weight liquid applications